卡格列净治疗2型糖尿病的疗效观察  

Observation on curative effect of canagliflozin in the treatment of type 2 diabetes mellitus

作　　者：应纪祥[1] 钟莉[1] 张婷[2] 卢春燕[3] 邹世月 曾慧 杨敏 YING Ji-xiang;ZHONG Li;ZHANG Ting;LU Chun-yan;ZOU Shi-yue;ZENG Hui;YANG Min(Department of Endocrinology,The First People’s Hospital of Longquanyi District,Chengdu 610100,China;Department of Clinical Laboratory,The First People’s Hospital of Longquanyi District,Chengdu 610100,China;Department of Endocrinology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]成都市龙泉驿区第一人民医院内分泌科,四川成都610100 [2]成都市龙泉驿区第一人民医院检验科,四川成都610100 [3]四川大学华西医院内分泌科,四川成都610041

出　　处：《实用医院临床杂志》2023年第4期153-157,共5页Practical Journal of Clinical Medicine

基　　金：四川省医学会伤口疾病(泰阁)专项科研课题(编号:2021TG65);成都市卫生健康委员会医学科研课题(编号:2020020)。

摘　　要：目的探讨卡格列净治疗2型糖尿病患者的疗效。方法收集2020年9月至2021年5月收治的2型糖尿病患者72例,按随机数字法分为试验组和对照组各36例,分别给予卡格列净或二甲双胍治疗6月,比较两组治疗前后糖化血红蛋白、空腹血糖、腰围、体重、尿酸、血脂、尿量、24小时尿电解质等。结果治疗6月后,两组空腹血糖、糖化血红蛋白均明显下降,组间比较差异无统计学意义(P>0.05)。治疗6月,试验组体重、体重指数、腰围较基线下降,差异均有统计学意义(P<0.01);但对照组较基线无统计学差异(P>0.05);试验组较对照组体重指数、腰围下降更多,差异有统计学意义(P<0.05)。试验组尿酸(UA)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)较基线改善(P<0.05);对照组LDL-C升高(P<0.05),治疗后试验组UA、LDL-C、TC较对照组低,HDL-C高(P<0.05)。对照组治疗前后尿量及尿电解质变化无统计学意义(P>0.05)。试验组治疗3月时尿量较基线增加,治疗3、6月时尿钠、尿镁及治疗6月时尿磷排泄量增加(P<0.05)。结论卡格列净降糖效果显著,能有效降低体重、减小腰围,降低UA、血脂,可使尿量出现短暂增加,可导致尿钠等尿电解质排泄增加。Objective To investigate the efficacy of canagliflozin(sodium-glucose cotransporter 2,SLGT2i)in the treatment of type 2 diabetes patients.Methods From September 2020 to May 2021,72 diabetics diagnosed and treated were selected.According to the random number method,the patients were divided into two groups:the treatment group treated with canagliflozin(ex-perimental group)and the metformin treatment group(control group).After taking canagliflozin orally for 6 months,glycosylated he-moglobin(HbA1c),fasting blood glucose(FPG),waistline,weight,uric acid(UA),blood lipid,urine volume and 24-hour urine electrolyte were compared before and after treatment.Results After 6 months of treatment,FPG and HbA1c significantly decreased in both groups;and there were no statistical difference between the groups(P>0.05).After 6 months of treatment,the weight,body mass index(BMI),and waistline of the experimental group decreased compared to the baseline,with significant statistical significance(P<0.01).However,there was no statistical difference between the control group and the baseline(P>0.05);The experimental group showed a greater decrease in BMI and waistline compared to the control group,with a statistically significant difference(P<0.05).In the experimental group,the levels of UA,total cholesterol(TC),low density lipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C)were improved(P<0.05).The control group had an increase in LDL-C(P<0.05).And after treatment,the experimental group had lower UA,LDL-C,TC,and higher HDL-C compared to the control group,with a statistically significant difference(P<0.05).There was no statistically significant difference in urine volume and electrolyte changes before and after treatment in the control group(P>0.05).Urine volume in the experimental group after 3 months of treatment was increased compared with baseline(P<0.05).Compared with the baseline,in the experimental group the excretion of urine sodium and magnesium after 3 and 6 months of treatment and phosphorus after 6

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 2型糖尿病 尿酸 血脂 尿电解质 

分 类 号：R587[医药卫生—内分泌]